MQS Management LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,052 shares of the biotechnology company's stock, valued at approximately $390,000.

A number of other institutional investors also recently modified their holdings of BMRN. Allspring Global Investments Holdings LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $1,811,000. Yousif Capital Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $228,000. Dupont Capital Management Corp bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $113,000. IndexIQ Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 26.9% in the fourth quarter. IndexIQ Advisors LLC now owns 4,000 shares of the biotechnology company's stock valued at $353,000 after purchasing an additional 849 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in shares of BioMarin Pharmaceutical by 40.1% in the fourth quarter. Toronto Dominion Bank now owns 36,158 shares of the biotechnology company's stock valued at $3,195,000 after purchasing an additional 10,344 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BMRN shares. Jefferies Financial Group reiterated a "buy" rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, May 4th. Cantor Fitzgerald started coverage on BioMarin Pharmaceutical in a report on Tuesday, July 12th. They set an "overweight" rating and a $110.00 target price on the stock. Barclays upped their target price on BioMarin Pharmaceutical from $112.00 to $125.00 and gave the stock an "overweight" rating in a report on Thursday, August 4th. Wedbush reiterated a "hold" rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, June 24th. Finally, Credit Suisse Group upped their target price on BioMarin Pharmaceutical to $111.00 in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $110.93.

Insider Activity

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $95.07 on Friday. BioMarin Pharmaceutical Inc. has a twelve month low of $70.73 and a twelve month high of $97.76. The business's 50 day moving average price is $83.95 and its two-hundred day moving average price is $82.44. The company has a quick ratio of 3.69, a current ratio of 5.42 and a debt-to-equity ratio of 0.24. The company has a market cap of $17.63 billion, a PE ratio of 365.67, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.78% and a net margin of 2.83%. During the same period in the prior year, the business earned $0.23 EPS. On average, analysts predict that BioMarin Pharmaceutical Inc. will post 0.92 EPS for the current year.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading

• Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
• Can You Guess Which EV Stock Is Beating Tesla ?
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?
• Find and Profitably Trade Stocks at 52-Week Lows
• Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating).

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.